Abstract:Summary Introduction Sodium‐glucose co‐transporter 2 inhibitors are a novel class of antihyperglycaemic drugs used in the management of type 2 diabetes, that improve glycaemic control, cardiovascular outcomes and promote weight loss. They are also approved for the treatment of heart failure and chronic kidney disease in patients with or without diabetes. This narrative review discusses the peri‐operative effects and implications of sodium‐glucose co‐transporter 2 inhibitors and gives an overview of current evidence and existing peri‐operative guidelines. Methods We conducted a literature review to identify peer‐reviewed English language articles published since 2000, with further articles identified by reviewing the references of key papers. Results Peri‐operative sodium‐glucose cotransporter 2 inhibitor use carries a risk of euglycaemic ketoacidosis. Although clinically significant diabetic ketoacidosis remains a rare event, sodium‐glucose co‐transporter 2 inhibitors inhibitor‐associated diabetic ketoacidosis has been observed across almost all surgical specialities. Ketoacidosis may present with any blood glucose level. Existing guidelines are inconsistent and may be a source of clinical confusion. Discussion Based on the half‐life of sodium‐glucose cotransporter 2 inhibitors, we recommend withholding treatment for 72 h before elective surgery (5 half‐lives), with additional multidisciplinary input for specific procedures with dietary alterations and in patients with poorly controlled diabetes of cardiac/renal disease. In the event of emergency surgery or any surgery within 72 h of sodium‐glucose cotransporter 2 inhibitor administration, we recommend pre‐, intra‐ and postoperative blood ketone monitoring (6 hourly for 24 h post‐surgery and until full oral diet is resumed). Sodium‐glucose cotransporter 2 inhibitor treatment should only be resumed after resumption of full oral diet in the absence of ketosis.

The effect of preoperative sodium-glucose cotransporter 2 inhibitors on the incidence of perioperative metabolic acidosis: A retrospective cohort study

Incidence of sodium–glucose cotransporter-2 inhibitor-associated perioperative ketoacidosis in surgical patients: a prospective cohort study

The peri‐operative implications of sodium‐glucose co‐transporter 2 inhibitors: a narrative review

Missed postoperative metabolic acidosis associated with sodium-glucose transporter 2 inhibitors in cardiac surgery patients: a retrospective analysis

Sodium-glucose cotransporter-2 inhibitors: an overview and perioperative implications

Comment on Umapathysivam et al. Euglycemic Ketoacidosis in Two Patients Without Diabetes After Introduction of Sodium–Glucose Cotransporter 2 Inhibitor for Heart Failure With Reduced Ejection Fraction. Diabetes Care 2024;47:140–143

Effect of Sodium–Glucose Cotransporter 2 (SGLT2) Inhibitors on Diabetic Ketoacidosis among Type 2 Diabetes Patients: A Meta-analysis of Randomized Controlled Trials Short running title: SGLT2 inhibitors and Diabetic Ketoacidosis

Association of sodium glucose co-transporter-2 inhibitors with risk of diabetic ketoacidosis among hospitalized patients: A multicentre cohort study

Effect Of Sodium-Glucose Cotransporter 2 Inhibitors On Diabetic Ketoacidosis Among Patients With Type 2 Diabetes: A Meta-Analysis Of Randomized Controlled Trials

Effect of Sodium–Glucose Cotransporter 2 Inhibitors on Diabetic Ketoacidosis among Patients with Type 2 Diabetes: A Meta-analysis of Randomized Controlled Trials

Diabetic Ketoacidosis as an Effect of Sodium-Glucose Cotransporter 2 Inhibitor: Real World Insights

Efficacy of Chronic Use of Sodium–Glucose Co-transporter 2 Inhibitors on the Prevention of Contrast-Induced Acute Kidney Injury in Patients with Type 2 Diabetes Mellitus Following Coronary Procedures: A Systematic Review and Meta-Analysis

Risk of ICU Admission and Related Mortality in Patients With Sodium-Glucose Cotransporter 2 Inhibitors and Dipeptidyl Peptidase-4 Inhibitors: A Territory-Wide Retrospective Cohort Study

Sodium glucose co-transporter-2 inhibitors in intensive care unit patients with type 2 diabetes: a pilot case control study

Perioperative use of glucagon-like peptide-1 receptor agonists and sodium-glucose cotransporter 2 inhibitors for diabetes mellitus

Euglycemic Ketoacidosis in a Patient without Diabetes Taking Sodium-Glucose Cotransporter 2 Inhibitors for Heart Failure

The effect of sodium-glucose cotransporter 2 inhibitors in patients with chronic kidney disease with or without type 2 diabetes mellitus on cardiovascular and renal outcomes: A systematic review and meta-analysis

Effect of SGLT2 inhibitors on cardiovascular, renal and safety outcomes in patients with type 2 diabetes mellitus and chronic kidney disease: A systematic review and meta‐analysis

Comparative effects of sodium–glucose cotransporter 2 inhibitors versus dipeptidyl peptidase-4 inhibitors on kidney function decline in Japanese individuals with type 2 diabetes

Comparison over Time of Adverse Drug Reactions in Diabetes Patients Treated with Sodium-Glucose Cotransporter 2 Inhibitors

Safety and Effectiveness of Sodium-Glucose Cotransporter 2 Inhibitor Combined with Medical Nutrition Therapy for Hyperglycemia in Acute Stroke: A Retrospective Study